Amgen reports Phase 3 results and Amgen stock trades at EUR 371.13
AD HOC NEWS
Amgen reported positive Phase 3 results for dazodalibep in systemic Sjogren's disease on September 22, 2026, which showed statistically significant and clinically meaningful improvement. The company also announced strong second-quarter revenue of USD 10.05 billion, up 9.50 percent, and maintained its full-year adjusted earnings-per-share guidance. Amgen stock was trading at EUR 371.13 at Lang & Schwarz on October 1, 2026, slightly down from its prior close, with its next earnings date scheduled
Read the full story
This is a short summary. The complete article is published by AD HOC NEWS.
Headline and summary aggregated from public news feeds. For information only — not financial advice.